Fig. 4.

Model of nanoformulations for two-stage drug delivery. G3 telodendrimers and cationic lipidoids self-assemble into positively-charged nanoparticles (TL-NP) to encapsulate Mcl-1 inhibitors with large particle sizes (>100 nm), which readily target circulating HCMV-infected blood monocytes to delivery Mcl-1 small-molecule inhibitors. G2 telodendrimers self-assemble into nanoparticles (T-NP) to encapsulate Mcl-1 inhibitors with small particle sizes (<50 nm) and a neutral surface. T-NP is able to penetrate through leaky blood vessels and diffuse deep into the inflamed tissue to deliver Mcl-1 inhibitors into HCMV-infected monocytes/macrophages within diseased organs.